159 related articles for article (PubMed ID: 24394088)
1. [Effect of enteral nutrition enriched with eicosapentaenoic acid on body weight loss and compliance with S-1 adjuvant chemotherapy after gastric cancer surgery].
Aoyama T; Hayashi T; Fujikawa H; Ogata T; Cho H; Wada H; Kitani Y; Yukawa N; Oshima T; Rino Y; Ozawa Y; Masuda M; Yoshikawa T
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2289-91. PubMed ID: 24394088
[TBL] [Abstract][Full Text] [Related]
2. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
[TBL] [Abstract][Full Text] [Related]
3. Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer.
Aoyama T; Sato T; Maezawa Y; Kano K; Hayashi T; Yamada T; Yukawa N; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
Int J Clin Oncol; 2017 Jun; 22(3):476-483. PubMed ID: 28176023
[TBL] [Abstract][Full Text] [Related]
4. A Phase III trial to evaluate the effect of perioperative nutrition enriched with eicosapentaenoic acid on body weight loss after total gastrectomy for T2-T4a gastric cancer.
Yoshikawa T; Hiki N; Taguri M; Sano T; Nunobe S; Taniguchi H; Fukushima R; Cho H; Morita S; Tsuburaya A
Jpn J Clin Oncol; 2012 May; 42(5):459-62. PubMed ID: 22389273
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of body weight loss in gastrectomy patients who underwent only surgery and those who underwent surgery followed up with S-1 adjuvant chemotherapy].
Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Ogata T; Cho H; Yukawa N; Oshima T; Rino Y; Ozawa Y; Kitani Y; Wada H; Masuda M; Tsuburaya A
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1794-6. PubMed ID: 23267889
[TBL] [Abstract][Full Text] [Related]
6. [Effect of Post-Gastrectomy Adjuvant S-1 Chemotherapy on Muscle Volume in Gastric Cancer Patients].
Iwazawa T; Kawanishi K; Fujita J; Takata A; Hirota M; Imamura H; Ikeda A; Hokonohara K; Yoneyama C; Kameyama A; Shinke G; Oshima K; Tanida T; Hatano H; Noda T; Komori T; Morita S; Akagi K; Dono K
Gan To Kagaku Ryoho; 2015 Aug; 42(8):957-60. PubMed ID: 26321709
[TBL] [Abstract][Full Text] [Related]
7. [A case report of advanced gastric cancer with increased C-reactive protein(CRP) and decreased albumin levels: chemotherapy with nutritional supportive care using eicosapentaenoic acid (EPA)-enriched enteral nutrition agent].
Imamura H; Kawase T; Kawabata R; Fujii C; Izeki C; Fukunaga M; Ohzato H
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2366-8. PubMed ID: 23268079
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
[TBL] [Abstract][Full Text] [Related]
9. [Examination of continuity of S-1 adjuvant chemotherapy for gastric cancer patients after gastrectomy].
Kawabata R; Imamura H; Kishimoto T; Anami S; Yasui Y; Fujino M; Fujii C; Sumida R; Furukawa H
Gan To Kagaku Ryoho; 2011 May; 38(5):793-5. PubMed ID: 21566439
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study.
Yamashita K; Kurokawa Y; Yamamoto K; Hirota M; Kawabata R; Mikami J; Masuzawa T; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2017 Sep; 24(9):2639-2645. PubMed ID: 28608116
[TBL] [Abstract][Full Text] [Related]
11. Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer.
Jeong JH; Ryu MH; Ryoo BY; Lee SS; Park I; Lee SH; Kim KC; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2012 Oct; 70(4):523-9. PubMed ID: 22864947
[TBL] [Abstract][Full Text] [Related]
12. [Induction of liaison-clinical pathway for patients with gastric cancer undergoing adjuvant chemotherapy using S-1 after curative gastrectomy].
Imamura H; Anami S; Watanabe M; Kishimoto T; Miyazaki Y; Kato H; Usui T; Masutani S; Tomotsu K; Furukawa H
Gan To Kagaku Ryoho; 2008 Aug; 35(8):1361-5. PubMed ID: 18701849
[TBL] [Abstract][Full Text] [Related]
13. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
Namikawa T; Munekage E; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Anticancer Res; 2014 Dec; 34(12):7297-301. PubMed ID: 25503163
[TBL] [Abstract][Full Text] [Related]
14. Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer.
Aoyama T; Kawabe T; Fujikawa H; Hayashi T; Yamada T; Tsuchida K; Yukawa N; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
Ann Surg Oncol; 2015 Aug; 22(8):2560-6. PubMed ID: 25515199
[TBL] [Abstract][Full Text] [Related]
15. [Examination of factors influencing continuity of S-1 adjuvant chemotherapy for gastric cancer patients].
Kawabata R; Imamura H; Kishimoto T; Hachino Y; Yasui Y; Fujino M; Fujii C; Fukunaga M; Ohzato H; Furukawa H
Gan To Kagaku Ryoho; 2012 Aug; 39(8):1205-8. PubMed ID: 22902443
[TBL] [Abstract][Full Text] [Related]
16. [The role of adjuvant chemotherapy with S-1 for gastric cancer patients].
Kitagawa M; Ichikawa D; Okamoto K; Shiozaki A; Fujiwara H; Kuriu Y; Ikoma H; Nakanishi M; Ochiai T; Sakakura C; Kokuba Y; Sonoyama T; Otsuji E
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1917-9. PubMed ID: 20948256
[TBL] [Abstract][Full Text] [Related]
17. [Pilot study of neo-adjuvant chemotherapy involving intraperitoneal administration of paclitaxel and oral S-1 for patients with T3 gastric cancer].
Tamura S; Miki H; Okada K; Yoshimura M; Uji K; Yoshida A; Suzuki R; Nakahira S; Egawa C; Nakata K; Okamura S; Sugimoto K; Takatsuka Y
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2024-6. PubMed ID: 19106511
[TBL] [Abstract][Full Text] [Related]
18. Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer.
Hasegawa H; Fujitani K; Kurokawa Y; Hirao M; Nakazuru S; Mita E; Tsujinaka T
Chemotherapy; 2010; 56(6):436-43. PubMed ID: 21088394
[TBL] [Abstract][Full Text] [Related]
19. Randomized clinical trial comparing standard diet with perioperative oral immunonutrition in total gastrectomy for gastric cancer.
Ida S; Hiki N; Cho H; Sakamaki K; Ito S; Fujitani K; Takiguchi N; Kawashima Y; Nishikawa K; Sasako M; Aoyama T; Honda M; Sato T; Nunobe S; Yoshikawa T
Br J Surg; 2017 Mar; 104(4):377-383. PubMed ID: 28072447
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy.
Ishido K; Azuma M; Koizumi W; Takeuchi A; Sakuramoto S; Watanabe M; Okayasu I
Pharmacogenet Genomics; 2009 Dec; 19(12):955-64. PubMed ID: 19898266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
